Nothing Special   »   [go: up one dir, main page]

WO2002018616A1 - Ajustement du rendement d'amplification d'une matrice d'acide nucleique par pcr attenuee a l'aide d'oligonucleotides matrices-genocopies - Google Patents

Ajustement du rendement d'amplification d'une matrice d'acide nucleique par pcr attenuee a l'aide d'oligonucleotides matrices-genocopies Download PDF

Info

Publication number
WO2002018616A1
WO2002018616A1 PCT/US2001/027287 US0127287W WO0218616A1 WO 2002018616 A1 WO2002018616 A1 WO 2002018616A1 US 0127287 W US0127287 W US 0127287W WO 0218616 A1 WO0218616 A1 WO 0218616A1
Authority
WO
WIPO (PCT)
Prior art keywords
template
primer
pcr
amplification
sequence
Prior art date
Application number
PCT/US2001/027287
Other languages
English (en)
Inventor
Song-Hua Ke
Original Assignee
Hitachi Chemical Co., Ltd.
Hitachi Chemical Research Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi Chemical Co., Ltd., Hitachi Chemical Research Center, Inc. filed Critical Hitachi Chemical Co., Ltd.
Publication of WO2002018616A1 publication Critical patent/WO2002018616A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • the invention relates to nucleic acid template amplification, and particularly to a method for adjusting the amplification efficiency of an abundant target without affecting the amplification of other targets in a DNA synthesis reaction.
  • the invention may be used in PCR or any other primer dependent DNA amplification technology.
  • Endogenous gene transcripts such as ⁇ -actin, glyceraldehyde-3 -phosphate dehydrogenase (GAPDH), or 18S rRNA are usually used as internal controls for quantification of gene expression to prevent variations in the final detection from tube to tube, or from experiment to experiment (BioTechniques, 2000,
  • the present invention provides a new attenuated PCR method for adjusting the efficiency of target template nucleic acid amplification by controlling the ratio of templatelike oligos (template-mimic oligos, TMOs) to amplification primers.
  • templatelike oligos template-mimic oligos, TMOs
  • the TMOs have sequences complementary to amplification primers.
  • the amplification efficiency of target template can be easily adjusted by controlling the ratio of template-mimic oligos to amplification primers with a 100% inhibition capacity.
  • the present invention provides a method of modulating amplification efficiency of a target sequence in primer-dependent polyrnerase-mediated DNA synthesis, comprising: (a) adding a template-mimic oligonucleotide to a primer- dependent polyrnerase-mediated DNA synthesis reaction mixture including primers, in an amount effective to block a primer effective to amplify a target sequence in the mixture from hybridizing to the target sequence, said template-mimic oligonucleotide having a sequence complimentary to said primer, said template-mimic oligonucleotide being inactive on primer-dependent polyrnerase-mediated DNA synthesis; and (b) conducing primer-dependent polyrnerase-mediated DNA synthesis reaction.
  • the template-mimic oligonucleotide may have a 3' terminal modified to prevent its extension by DNA polymerase.
  • the 3' terminal modification includes chemically modification; the addition of a dideoxynucleotide, phosphate, biotin, digoxygenin, fluorescein, an amine, a thiol, an azo (N 3 ) group, or fluorine; and modification by phosphorylation or biotinylation.
  • the template-mimic oligonucleotide is an RNA, or a DNA RNA chimera. Further, if the template-mimic oligonulceotide is exclusively complementary to the primer, amplification of other sequences, if any, in the primer-dependent polyrnerase- mediated DNA synthesis is not affected.
  • a template of the target sequence may be a ⁇ -actin, 18S, 28S, or 5S ribosomal, or glyceraldehyde 3-P phosphate dehydrogenase template.
  • the primer-dependent polyrnerase-mediated DNA synthesis reaction includes an end-point RT-PCR reaction, an end-point PCR reaction, a real-time RT-PCR reaction, and a real-time PCR reaction, for example.
  • the present invention provides a method of multiplex thermal cycling, primer-dependent, polyrnerase-mediated DNA synthesis, comprising: (a) providing a primer-dependent polyrnerase-mediated DNA synthesis reaction mixture including at least one primer pair effective to amplify sequences including a target sequence; (b) placing at least one template-mimic oligonucleotide in said reaction mixture in an amount effective to modulate amplification efficiency of the target sequence by a primer, each template-mimic oligonucleotide having a sequence complimentary to said primer, said template-mimic oligonucleotide being inactive on primer-dependent polyrnerase-mediated DNA synthesis; and (c) conducing multiplex thermal, primer- dependent, polyrnera
  • the present invention provides a method of attenuated PCR, comprising: (a) providing a PCR mixture; (b) placing at least one template-mimic oligonucleotide in said mixture in an amount effective to modulate amplification efficiency of a target sequence by a primer, each template-mimic oligonucleotide having a sequence complimentary to said primer, said template-mimic oligonucleotide being inactive on PCR synthesis; and (c) conducing PCR.
  • the present invention provides a method of attenuated PCR, comprising: (a) providing a PCR mixture including a standard sequence, primers to amplify the standard sequence, at least one target sequence, and primers to amplify the target sequence; (b) placing a template-mimic oligonucleotide having a sequence complimentary to said primer for the standard sequence in said mixture in an amount effective to modulate amplification efficiency of the standard sequence, said template- mimic oligonucleotide having a non-extendable 3' terminal; and (c) conducing PCR while maintain amplification of said standard sequence in a linear range concurrently with linear amplification of said target sequence.
  • the present invention can be applied to an attenuated PCR kit comprising (a) an amplification primer and (b) a template-mimic oligonucleotide having a sequence complimentary to said primer, said template-mimic oligonucleotide having a non- extendable 3' terminal.
  • FIGS la and lb show schematic outlines of attenuated PCR and standard PCR, respectively.
  • attenuated PCR both amplification primers and template-mimic oligos (TMOs) are used in the reaction.
  • TMOs template-mimic oligos
  • TMOs compete with templates for binding of amplification oligos. Only the templates hybridized with amplification primers will be amplified.
  • Figure 2 shows electrophoresis bands of ⁇ -actin and Caspase 9, indicating the effect of ⁇ -actin TMO on template amplification in an embodiment.
  • concentrations of the template-mimic oligo are as follows: Lane 1 - 2000 nM, Lane 2 - 1600 nM, lane 3 - 1200 nM, lane 4 - 800 nM, Lane 5 - 600 nM, lane 6 - 400 nM, Lane 7 - 300 nM, Lane 8 - 200 nM, Lane 9 - 150 nM, Lane 10 - 100 nM, Lane 11 and 12 - 0 nM.
  • TMO indicating the effect of ⁇ -actin TMO on template amplification in an embodiment.
  • ⁇ -actin amplification amplification primer - 200 nM; template - 50 pg/ ⁇ l.
  • Caspase 9 amplification amplification primer - 200 nM; template - 5 pg/ ⁇ l. 30 cycles PCR; 30 ⁇ l reaction.
  • Figure 4 shows the relationship between percentage of inhibition (%) and TMO concentration, indicating inhibition efficiency of TMO in an embodiment.
  • Figure 5 shows electrophoresis bands of ⁇ -actin, indicating the effect of ⁇ -actin Competimer on template amplification in an embodiment.
  • Competimer are as follows: Lane 1 - 1600 nM, lane 2 and 9 - 1200 nM, lane 3 and 10 - 800 nM, lane 4 and 11 - 400 nM, lane 5 and 12 - 200 nM, lane 6 and 13 - 100 nM, lane 7 and 14 - 0 nM. Lanes 1-7: ⁇ -Actin PCR with 200 nM amplification primers; lanes 9-14: ⁇ - actin PCR with 61 nM amplification primers. Template - 50 pg/ ⁇ l; 30 cycles PCR; 20 ⁇ l reaction.
  • Figure 6 shows the relationship between band intensity (unit) and Competimer concentration, indicating the effect of ⁇ -actin Competimer on ⁇ -actin PCR amplification in an embodiment.
  • (•) ⁇ -actin PCR with 200 nM amplification primers, (o), ⁇ -actin PCR with 61 nM amplification primers. Template - 50 pg/ ⁇ l; 30 cycles PCR; 20 ⁇ l reaction.
  • Figure 7 shows the relationship between percentage of inhibition and Competimer concentration (nM), indicating inhibition efficiency of Competimer in ⁇ -actin PCR amplification.
  • (•) ⁇ -actin PCR with 200 nM amplification primers, (o), ⁇ -actin PCR with 61 nM amplification primers. Template - 50 pg/ ⁇ l; 30 cycles PCR; 20 ⁇ l reaction.
  • Figure 8 shows electrophoresis bands of p53 and ⁇ -actin, indicating dynamic range of attenuated PCR.
  • Lanes 1-7 600 nM ⁇ -actin template-mimic oligo; lanes 8 - 14: no ⁇ - actin template-mimic oligo; M - 100 bp DNA marker.
  • Lane 1 and 8 1 ng/ ⁇ l of ⁇ -actin template and 0.01 ng/ ⁇ l of p53 template
  • lane 2 and 9 0.1 ng/ ⁇ l of ⁇ -actin template and 1 pg/ ⁇ l of p53 template
  • lane 3 and 10 0.01 ng/ ⁇ l of ⁇ -actin template and 0.1 pg/ ⁇ l of p53 template
  • lane 4 and 11 1 pg/ ⁇ l of ⁇ -actin template and 0.01 pg/ ⁇ l of p53 template
  • lane 5 and 12 0.1 pg/ ⁇ l of ⁇ -actin template and 1 fg/ ⁇ l of p53 template
  • lane 6 and 13 0.01 pg/ ⁇ l of ⁇ -actin template and 0.1 fg/ ⁇ l of p53 template
  • lane 7 and 14 1 fg/ ⁇ l of ⁇ -actin template and 0.01 fg/ ⁇ l of p53 template.
  • Figure 9 shows the relationship between DNA band intensity (unit) and log (picogram/ ⁇ l) of initial template in each amplification, indicating a dynamic range of attenuated PCR amplification of ⁇ -actin and p53.
  • (•) ⁇ -actin amplification with 600 nM ⁇ - actin TMO;
  • (o) ⁇ -actin amplification without ⁇ -actin TMO;
  • ⁇ p53 amplification without ⁇ -actin TMO.
  • Figures 10a and 10b show the relationship between PCR base line subtracted RFU and cycles, indicating effectiveness of attenuated real-time PCR (Figure 10b), where 200 nM of each ⁇ -actin TMO was used in each reaction, compared to standard real-time PCR ( Figure 10a).
  • ( ⁇ ) 2 pg/ ⁇ l of ⁇ -actin template;
  • Figure 11 shows the relationship between threshold cycle (Ct) and log (template amount, ng), indicating standard curves for ⁇ -actin cDNA from regular real-time PCR (•) and attenuated real-time PCR (o) reactions. These curves are generated from the data of figure 10 by plotting the C t values against the logarithm of the initial template concentration (ng/ ⁇ l). The C t value is inversely proportional to the log of the initial initial template concentration. For the same amount of template, the C t values are increased from the attenuated real-time PCR comparing with the values from the regular real-time PCR. The results suggest that TMO can attenuate the real-time PCR amplification efficiency.
  • Ct threshold cycle
  • log template amount, ng
  • Figure 12 shows electrophoresis bands of Casepase9 and ⁇ -actin, indicating RT- PCR detection of Caspase 9 gene.
  • Lane 1-3 75,000 Hs578T cells/well; Lane 4-5: 300,000 U937 cells/well.
  • the new attenuated PCR method for adjusting the efficiency of target template nucleic acid amplification by controlling the ratio of template-mimic oligos (TMOs) to amplification primers will be described.
  • the TMOs have sequences complementary to amplification primers. In hybridization steps of PCR, the TMOs bind to amplification primers and prevent them from binding to templates for polymerization synthesis.
  • the invention includes applying TMOs to extend the dynamic linear range over several logs, perferably over 4 to 5 logs, of the initial input for a target template allowing easier quantification for both single and multiplex PCR.
  • the invention also includes applying TMOs to real-time PCR quantification.
  • the present invention also provides evidence that the existence of the TMOs in a multiplex PCR only affects the efficiency of the target sequence amplification without changing the amplification efficiency of other templates co-existing in the reaction.
  • the TMO-assisted attenuated PCR technology provides a convenient and efficient method for simultaneous detection of high and low- abundant genes in multiplex RT-PCR. The utility of this new strategy is demonstrated in quantitative detection of target genes such as ⁇ -actin, p53 and caspase-9.
  • the present invention may include the following steps: selecting internal control genes; designing amplification primers; designing TMOs which have sequences complementary to the amplification primers, the 3' end of each sequence being non- extendable; selecting target genes and amplification primers therefor; and conducting attenuated PCR, wherein the TMOs are used at a concentration effective to coordinate the efficiency of target gene amplification and the efficiency of internal control gene amplification.
  • Amplification primers can be designed using various types of primer-designing software including technology disclosed in U.S. patent application No. 07/974,409 filed November 12, 1992, entitled “Method and Reagent for Measuring Messenger RNA” which is incorporated herein by reference.
  • TMOs of the present invention have sequences complementary to amplification primers.
  • the length of each TMO may be 5 bases shorter to 50 bases longer than the complementary amplification primer (preferably 0-10 bases longer, more preferably 1-5 bases longer).
  • the minimum length of a TMO may be a hexamer.
  • the extra base sequence of the TMO is different from the corresponding template gene sequence.
  • the 3' end of each TMO may not be extendable, e.g., modified to block extension by DNA polymerase (adding a blocker or adding random sequences or any different sequences from the template).
  • the weight ratio of TMOs to amplification primers may be 0.1 to 15, preferably 1 to 7 (as measured when the TMO has a sequence for optimum hybridization to the primer), depending on the required level of inhibition of amplification efficiency.
  • Figures la and lb describe the method developed here to adjust the amplification efficiency of a target without affecting other templates amplification efficiencies.
  • two kinds of oligonucleotides are applied to a nucleic acid template.
  • One is a pair of amplification oligonucleotides or amplification primers, whose function is to serve as primers during hybridization and enzymatic synthesis process to amplify templates with DNA polymerases.
  • the two amplification oligonucleotides or primers are the regular oligonucleotides used in a standard PCR reaction.
  • the other kind is a pair of special oligos, which are not used in a standard PCR reaction. They are called template-mimic oligos (TMOs). Their function is to provide binding sites for the amplification oligos in the hybridization steps, but the hybridization does not provide enzymatic synthesis sites.
  • TMOs template-mimic oligos
  • the two TMOs have sequences complementary to two amplification oligos separately.
  • the 5' end base of each TMO is complementary to the 3' end base of the corresponding amplification oligo.
  • the 3' end of each TMO is about 5 bases (or more or less bases) longer or shorter than the corresponding amplification primer.
  • the optimal template-mimic oligos are 1 to 5 bases longer than the amplification primers at their 3' end.
  • the content of the extra base sequence in the TMO is different from the original template sequence.
  • the 3 ' end of the TMOs has been modified by any means in a way that blocks the TMO from extension by DNA polymerase, such as 3 ' addition of phosphate, biotin, a dideoxynucleotide, or a 3 '-3' linked 5' support blocker (which is commercially available from Operon Technologies or Glen Research).
  • the TMO can be a DNA, it also can be an RNA, an RNA/DNA chimera, or a PNA.
  • the TMO may be used not only in a PCR reaction, but also in other primer-dependent nucleic acid synthetic reactions, such as Self-Sustained Sequence Amplification (3SR) (PNAS, 1990, 87:1874-1878), or Nucleic
  • NASBA Acid Sequence-Based Amplification
  • Figures 2, 3 and 4 show the inhibition effect of ⁇ -actin TMO on ⁇ -actin DNA amplification.
  • caspase 9 was co-amplified with ⁇ -actin.
  • the top band at 580 bp position is caspase 9 PCR product in figure 2.
  • ⁇ -actin TMO concentration increases from 0 to 2000 nM
  • the intensity of caspase 9 DNA bands remains approximately constant, except at the low TMO concentration (less than 200 nM) where the caspase 9 products are lower than products from reactions at the high concentration of TMO (because of the reagents limitation caused by the consumption of ⁇ -actin template amplification).
  • Figures 5, 6 and 7 show the inhibition effect of ⁇ -actin "Competimer" on ⁇ -actin DNA amplification.
  • the Competimer can inhibit the ⁇ -actin template amplification as demonstrated in figure 5 and 6. But the maximum inhibition efficiency is less than 60% as shown in figure 7. At 800 nM of Competimer, the inhibition efficiency reaches the plateau stage. Contrary to the phenomena, TMO can have inhibition efficiency up to 100% as demonstrated in Figure 4. The two methods are compared and summarized in table 1. Table 1. Comparison of TMO Method with "Competimer" Technology
  • IC 50 is defined as the inhibition concentration of TMO at which 50% of maximum amplification efficiency is inhibited.
  • Figures 8 and 9 show PCR amplification with serially 10-fold diluted ⁇ -actin and p53 plasmid template DNAs.
  • ⁇ -actin plasmid template concentrations are 100-fold greater than p53 plasmid templates.
  • 600 nM of ⁇ -actin TMOs and 200 nM amplification primers for each template are employed.
  • 200 nM amplification primers are used.
  • Figure 9 suggests that the final products of attenuated PCR amplification depend on the initial template concentration.
  • the linear range of initial template concentration for attenuated PCR is about 4 to 5 logs of the concentration of input DNAs, while a regular PCR has 2.5 to 3 logs of input DNAs.
  • p53 target amplification it is essentially the same for both PCR reactions.
  • FIGS 10a, 10b, and 11 show that for the same amount of template, the C t values are increased from the attenuated real-time PCR comparing with the values from the regular real-time PCR.
  • the results suggest that TMO can attenuate the real-time PCR amplification efficiency. Attenuated RT-PCR.
  • the results presented in figure 12 show the competitive interference from ⁇ -actin amplification by regular RT-PCR reduce the amplification of caspase-9 gene.
  • TMO application in the multiplex attenuated RT-PCR can prevent the competitive interference from high-copy number genes such as ⁇ -actin gene in figure 12.
  • EXAMPLE Taq DNA polymerase and dNTP were purchased from Promega.
  • ⁇ -Actin cDNA, Caspase-9 cDNA and p53 cDNA plasmids were constructed by ligation of their cDNA fragments with pSP64 poly(A) vector (from Promega) or pCR2.1 (from Invitrogen).
  • DNA oligonucleotides were from Operon Inc. (Alameda, CA). Oligos used for the experiments presented in figures 2 through 9 are shown in Table 2.
  • * 3' te ⁇ riinator is a 5 '-support blocker which is an unmodified deoxynucleoside
  • PCR was carried out in a thermal cycler with a hot-lid from MJ. Research (PTC- 200). In a regular PCR, the PCR conditions were similar to the protocol recommended by Promega.
  • 30 ⁇ l reaction mixtures contained 0.03 fg -30 ng of plasmid DNAs, 61 nM or 200 nM of amplification primers, and 200 ⁇ M of each dNTP in a buffer of 10 mM Tris-HCl
  • Actin cDNA plasmids were constructed by ligation of ⁇ -actin cDNA fragments with pSP64 poly (A) vector (From Promega) in the lab. The plasmids were used as templates in realtime PCR. Pure dye calibration solution for iCycler iQ real-time PCR detection system was from Bio-Rad. DNA oligonucleotides and probes were from Operon Inc. (Alameda, CA). The oligonucleotide used as TaqMan probe was purified with HPLC.
  • the sequence of the TaqMan probe is:
  • the forward primer sequence is: 5' TGCGTGACATTAAGGAGAAG 3'.
  • the reverse primer is: 5' GCTCGTAGCTCTTCTCCA 3'. (SEQ ID NO: 15)
  • the TMO sequence for the forward primer is:
  • the TMO sequence for the reverse primer is:
  • PCR was carried out with a real-time PCR detection system named iCycler from Bio-Rad. 25 ⁇ l reaction mixtures containing 0.5 pg - 5.0 ng of template DNAs, 5 pmoles of each amplification primers, and 6 pmoles of the TaqMan probe were applied to the wells of a 96-well thin-wall PCR plate. For TMO-assisted attenuated PCR, 5 pmoles of each TMO were applied with other components for a regular PCR. The plate was covered with a piece of optical-quality sealing tape. PCR programs were 7 min at 95 °C, followed by 40 cycles of 30 sec at 95°C and 45 sec at 60°C. The fluorescent detection was set at 60°C step. The PCR reaction data was analyzed with the software provided by Bio-Rad and SigmaPlot and presented in figures 10A, 10B and 11.
  • End-point RT-PCR for samples from cultured cellsmRNA Express Kit for the purification of mRNA was from RNAture, Inc. Irvine CA.
  • U937 human lymphoma cells and Hs578T human breast cancer cells were cultured for the mRNA isolation.
  • 3x10 s U937 cells or 7.5x10 4 Hs578T cells were applied to each well in a 96-well GenePlate from the kit.
  • the procedure for mRNA isolation recommended by RNAture was followed.
  • the RT- reaction for cDNA production was conducted at 42 °C for 50 min in 20 ⁇ l reactions with 100 units of M-MLV Reverse Transcriptase (from Promega).
  • PCR was carried out in a thermal cycler with a hot-lid from M.J. Research (PTC-200).
  • the temperature cycles were 94°C for 40 sec (except for a 2 minute first cycle), 55°C for 50 sec. and 72°C for 50 sec. with a final extension step for 6 min at 72°C.
  • the experimental conditions were the same as regular PCR except 50 nM -2000 nM template-mimic oligos (TMO) were added into the reaction. 6 ⁇ l of each reaction was examined for size and purity on a 1.5% agarose or 4-20

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des oligonucléotides matrices-génocopies (TMO) modifiés permettant d'ajuster le rendement d'amplification d'une cible abondante sans affecter l'amplification d'autres cibles lors d'une réaction de synthèse d'ADN. L'invention peut être utilisé dans des PCR ou dans toute autre technique d'amplification d'ADN dépendant d'amorces.
PCT/US2001/027287 2000-09-01 2001-08-30 Ajustement du rendement d'amplification d'une matrice d'acide nucleique par pcr attenuee a l'aide d'oligonucleotides matrices-genocopies WO2002018616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23018400P 2000-09-01 2000-09-01
US60/230,184 2000-09-01

Publications (1)

Publication Number Publication Date
WO2002018616A1 true WO2002018616A1 (fr) 2002-03-07

Family

ID=22864244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027287 WO2002018616A1 (fr) 2000-09-01 2001-08-30 Ajustement du rendement d'amplification d'une matrice d'acide nucleique par pcr attenuee a l'aide d'oligonucleotides matrices-genocopies

Country Status (1)

Country Link
WO (1) WO2002018616A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016569A1 (fr) * 2001-08-20 2003-02-27 Takara Bio Inc. Methodes d'amplification d'acide nucleique
EP1435394A1 (fr) 2002-12-12 2004-07-07 Fuji Photo Film Co., Ltd. Méthode pour mesurer un acide nucléique
WO2006005235A1 (fr) * 2004-07-09 2006-01-19 Huadong Research Institute For Medicine And Biotechnics Procede de comparaison destine a la quantite d'expression pour le meme gene provenant de sources differentes par la mesure des sequences de base
EP2270203A1 (fr) * 2009-06-29 2011-01-05 AIT Austrian Institute of Technology GmbH Procédé d'hybridation oligonucléotide
US8361753B2 (en) 2006-06-01 2013-01-29 Trilink Biotechnologies, Inc. Phosphotriester-modified oligonucleotide primers for nucleic acid amplification
WO2012149339A3 (fr) * 2011-04-29 2013-03-14 Sequenom, Inc. Quantification d'une minorité d'espèces d'acide nucléique
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
WO2015063154A1 (fr) * 2013-10-31 2015-05-07 Multiplicom N.V. Amorces de blocage dans des essais à base de pcr multiplexe
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
EP3530754A1 (fr) * 2018-02-26 2019-08-28 AGCT GmbH Procédé d'amplification d'un acide nucléique à spécificité améliorée
EP3530753A1 (fr) * 2018-02-26 2019-08-28 AGCT GmbH Procédé de réaction d'extension des amorces à spécificité améliorée
WO2019162530A1 (fr) * 2018-02-26 2019-08-29 Agct Gmbh Procédé pour l'amplification d'un acide nucléique avec spécificité améliorée
WO2019162529A1 (fr) * 2018-02-26 2019-08-29 Agct Gmbh Procédé pour réaction d'allongement d'amorce avec une meilleure spécificité
WO2019166586A1 (fr) * 2018-02-28 2019-09-06 Agct Gmbh Procédé d'amplification d'un acide nucléique à spécificité améliorée
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US12176067B2 (en) 2012-12-20 2024-12-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487985A (en) * 1990-10-15 1996-01-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5618703A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Unconventional nucleotide substitution in temperature selective RT-PCR
US5759822A (en) * 1995-01-27 1998-06-02 Clontech Laboratories, Inc. Method for suppressing DNA fragment amplification during PCR
US5874215A (en) * 1995-01-16 1999-02-23 Keygene N.V. Amplification of simple sequence repeats

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618703A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Unconventional nucleotide substitution in temperature selective RT-PCR
US5487985A (en) * 1990-10-15 1996-01-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5874215A (en) * 1995-01-16 1999-02-23 Keygene N.V. Amplification of simple sequence repeats
US5759822A (en) * 1995-01-27 1998-06-02 Clontech Laboratories, Inc. Method for suppressing DNA fragment amplification during PCR

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056671B2 (en) 2001-08-20 2006-06-06 Takara Bio Inc. Isothermal chimeric primer nucleic acid amplification methods using blocking oglionucleotide
WO2003016569A1 (fr) * 2001-08-20 2003-02-27 Takara Bio Inc. Methodes d'amplification d'acide nucleique
EP1435394A1 (fr) 2002-12-12 2004-07-07 Fuji Photo Film Co., Ltd. Méthode pour mesurer un acide nucléique
WO2006005235A1 (fr) * 2004-07-09 2006-01-19 Huadong Research Institute For Medicine And Biotechnics Procede de comparaison destine a la quantite d'expression pour le meme gene provenant de sources differentes par la mesure des sequences de base
US8361753B2 (en) 2006-06-01 2013-01-29 Trilink Biotechnologies, Inc. Phosphotriester-modified oligonucleotide primers for nucleic acid amplification
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US10612086B2 (en) 2008-09-16 2020-04-07 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP2270203A1 (fr) * 2009-06-29 2011-01-05 AIT Austrian Institute of Technology GmbH Procédé d'hybridation oligonucléotide
WO2011000836A1 (fr) 2009-06-29 2011-01-06 Ait Austrian Institute Of Technology Gmbh Procédé d'hybridation d'oligonucléotides
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
US11180799B2 (en) 2009-12-22 2021-11-23 Sequenom, Inc. Processes and kits for identifying aneuploidy
EP3378954A1 (fr) * 2011-04-29 2018-09-26 Sequenom, Inc. Quantification d'une minorité d'espèces d'acide nucléique
CN103717750A (zh) * 2011-04-29 2014-04-09 塞昆纳姆股份有限公司 少数核酸物质的定量
CN103717750B (zh) * 2011-04-29 2017-03-08 塞昆纳姆股份有限公司 少数核酸物质的定量
AU2012249531B2 (en) * 2011-04-29 2017-06-29 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2012149339A3 (fr) * 2011-04-29 2013-03-14 Sequenom, Inc. Quantification d'une minorité d'espèces d'acide nucléique
US11312997B2 (en) 2012-03-02 2022-04-26 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10738359B2 (en) 2012-03-02 2020-08-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11306354B2 (en) 2012-05-21 2022-04-19 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US12176067B2 (en) 2012-12-20 2024-12-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
WO2015063154A1 (fr) * 2013-10-31 2015-05-07 Multiplicom N.V. Amorces de blocage dans des essais à base de pcr multiplexe
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2019162529A1 (fr) * 2018-02-26 2019-08-29 Agct Gmbh Procédé pour réaction d'allongement d'amorce avec une meilleure spécificité
WO2019162530A1 (fr) * 2018-02-26 2019-08-29 Agct Gmbh Procédé pour l'amplification d'un acide nucléique avec spécificité améliorée
CN112074612A (zh) * 2018-02-26 2020-12-11 Agct有限公司 一种具有更高特异性的核酸扩增方法
EP3530753A1 (fr) * 2018-02-26 2019-08-28 AGCT GmbH Procédé de réaction d'extension des amorces à spécificité améliorée
EP3530754A1 (fr) * 2018-02-26 2019-08-28 AGCT GmbH Procédé d'amplification d'un acide nucléique à spécificité améliorée
WO2019166586A1 (fr) * 2018-02-28 2019-09-06 Agct Gmbh Procédé d'amplification d'un acide nucléique à spécificité améliorée

Similar Documents

Publication Publication Date Title
WO2002018616A1 (fr) Ajustement du rendement d'amplification d'une matrice d'acide nucleique par pcr attenuee a l'aide d'oligonucleotides matrices-genocopies
Parker et al. Targeted gene walking polymerase chain reaction
EP2927238A1 (fr) Procédé d'amplification d'acide nucléique
FR2683827B1 (fr) Procede de determination de la quantite d'un fragment d'adn d'interet par une methode d'amplification enzymatique.
US8486628B2 (en) Method of normalized quantification of nucleic acids using anchor oligonucleotides and adapter oligonucleotides
KR910014510A (ko) 폴리머라제 및 리가제 쇄 반응 모두에 적용할 수 있는 표적 핵산을 증폭시키는 방법
CA2971006C (fr) Amplification d'acides nucleiques superieure a 2 sur une base exponentielle
EP3478853B1 (fr) Améliorations de ou concernant des procédés d'amplification d'acides nucléiques
CA2318371A1 (fr) Procede de detection de sequences nucleotidiques
AU2019371797A1 (en) Exponential base-3 nucleic acid amplification with reduced amplification time using nested overlapping primers
EP4019647B1 (fr) Réactions d'amplification multiplex et multi-étape modifiées et réactifs associés
EP3735474B1 (fr) Améliorations de l'amplification d'acides nucléiques ou se rapportant à celle-ci
JP2012506246A (ja) 内部正規化を用いるｒｎａの定量
EP2163556A1 (fr) Polyanion pour amplification améliorée d'acide nucléique
US20070122827A1 (en) Target nucleic acid signal detection
EP3768859B1 (fr) Méthodes d'amplification d'acides nucléiques avec équilibre de décalage à médiation par endonucléase (em-seq)
JP2023520203A (ja) 核酸ライブラリを調製するための方法及び組成物
US20020031776A1 (en) Enzymatic labeling and detection of DNA hybridization probes
Kinoshita et al. A heteroduplex-preferential Tm depressor for the specificity-enhanced DNA polymerase chain reactions
US20210388431A1 (en) Thermokinetically balanced isothermal amplification of nucleic acid sequences
EP3759248A1 (fr) Procédé pour l'amplification d'un acide nucléique avec spécificité améliorée
EP2208797A2 (fr) Techniques, compositions et kits d'amplification de polynucleotide
Hui et al. Clinical reaction applications for molecular of pathology the polymerase chain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): DE FR GB IT

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP